229 related articles for article (PubMed ID: 24677287)
1. Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization.
Lelle M; Frick SU; Steinbrink K; Peneva K
J Pept Sci; 2014 May; 20(5):323-33. PubMed ID: 24677287
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.
Darwish S; Sadeghiani N; Fong S; Mozaffari S; Hamidi P; Withana T; Yang S; Tiwari RK; Parang K
Eur J Med Chem; 2019 Jan; 161():594-606. PubMed ID: 30396106
[TBL] [Abstract][Full Text] [Related]
3. Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties.
Soler M; González-Bártulos M; Soriano-Castell D; Ribas X; Costas M; Tebar F; Massaguer A; Feliu L; Planas M
Org Biomol Chem; 2014 Mar; 12(10):1652-63. PubMed ID: 24480922
[TBL] [Abstract][Full Text] [Related]
4. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
5. Delivering aminopyridine ligands into cancer cells through conjugation to the cell-penetrating peptide BP16.
Soler M; González-Bártulos M; Figueras E; Massaguer A; Feliu L; Planas M; Ribas X; Costas M
Org Biomol Chem; 2016 Apr; 14(17):4061-70. PubMed ID: 27055538
[TBL] [Abstract][Full Text] [Related]
6. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
[TBL] [Abstract][Full Text] [Related]
7. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
Liang JF; Yang VC
Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
[TBL] [Abstract][Full Text] [Related]
9. Thermosensitive magnetic liposomes with doxorubicin cell-penetrating peptides conjugate for enhanced and targeted cancer therapy.
Lin W; Xie X; Yang Y; Fu X; Liu H; Yang Y; Deng J
Drug Deliv; 2016 Nov; 23(9):3436-3443. PubMed ID: 27193383
[TBL] [Abstract][Full Text] [Related]
10. A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles.
Wang Y; Ma S; Xie Z; Zhang H
Colloids Surf B Biointerfaces; 2014 Apr; 116():41-8. PubMed ID: 24441457
[TBL] [Abstract][Full Text] [Related]
11. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery.
Du JZ; Du XJ; Mao CQ; Wang J
J Am Chem Soc; 2011 Nov; 133(44):17560-3. PubMed ID: 21985458
[TBL] [Abstract][Full Text] [Related]
12. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
13. Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
Tanaka M; Zhu Y; Shionyu M; Ota N; Shibata N; Watanabe C; Mizusawa A; Sasaki R; Mizukami T; Shiina I; Hasegawa M
Eur J Med Chem; 2018 Feb; 146():636-650. PubMed ID: 29407987
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity.
Gronewold A; Horn M; Ranđelović I; Tóvári J; Muñoz Vázquez S; Schomäcker K; Neundorf I
ChemMedChem; 2017 Jan; 12(1):42-49. PubMed ID: 27860402
[TBL] [Abstract][Full Text] [Related]
15. Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate.
Lelle M; Kaloyanova S; Freidel C; Theodoropoulou M; Musheev M; Niehrs C; Stalla G; Peneva K
Mol Pharm; 2015 Dec; 12(12):4290-300. PubMed ID: 26524088
[TBL] [Abstract][Full Text] [Related]
16. Zwitterionic guanidine-based oligomers mimicking cell-penetrating peptides as a nontoxic alternative to cationic polymers to enhance the cellular uptake of micelles.
Kim Y; Binauld S; Stenzel MH
Biomacromolecules; 2012 Oct; 13(10):3418-26. PubMed ID: 22946476
[TBL] [Abstract][Full Text] [Related]
17. Cell-penetrating peptide conjugates of gambogic acid enhance the antitumor effect on human bladder cancer EJ cells through ROS-mediated apoptosis.
Lyu L; Huang LQ; Huang T; Xiang W; Yuan JD; Zhang CH
Drug Des Devel Ther; 2018; 12():743-756. PubMed ID: 29670331
[TBL] [Abstract][Full Text] [Related]
18. Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.
Villa R; Cerroni B; Viganò L; Margheritelli S; Abolafio G; Oddo L; Paradossi G; Zaffaroni N
Colloids Surf B Biointerfaces; 2013 Oct; 110():434-42. PubMed ID: 23759384
[TBL] [Abstract][Full Text] [Related]
19. Protease-Responsive Prodrug with Aggregation-Induced Emission Probe for Controlled Drug Delivery and Drug Release Tracking in Living Cells.
Cheng Y; Huang F; Min X; Gao P; Zhang T; Li X; Liu B; Hong Y; Lou X; Xia F
Anal Chem; 2016 Sep; 88(17):8913-9. PubMed ID: 27503607
[TBL] [Abstract][Full Text] [Related]
20. Efficacious anticancer drug delivery mediated by a pH-sensitive self-assembly of a conserved tripeptide derived from tyrosine kinase NGF receptor.
Moitra P; Kumar K; Kondaiah P; Bhattacharya S
Angew Chem Int Ed Engl; 2014 Jan; 53(4):1113-7. PubMed ID: 24338837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
